Based on this notion, a study using the vitiligo mouse model demonstrated that anti-CD122 Ab depletes CD8+ TRM from vitiligo, thereby achieving durable repigmentation when administered either systemically or locally in the skin. The gene discussed is IL2RB; the disease is vitiligo.